AFM-24

Affimed, a leader in innate cell engager (ICE®) therapies, is making significant strides in the clinical development of novel treatments for solid and hematologic tumors. With over 500 patients treated, the company has demonstrated clinical efficacy across various indications, leveraging its proprietary IP targeting CD16A on NK cells and macrophages. Affimed's ongoing clinical programs, including AFM24, Acimtamig (AFM13), and AFM28, show promising results in treating advanced/metastatic NSCLC, R/R Classical HL, and R/R CD123+ AML, respectively. The company's innovative approach combines ICE® molecules with NK cell therapy and checkpoint inhibitors to enhance the immune system's ability to fight cancer.

Affimed's AFM24 combined with atezolizumab demonstrates meaningful clinical activity in heavily pretreated non-small cell lung cancer (NSCLC) patients, including those with EGFR mutations.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.

Affimed N.V., a leader in innate cell engager (ICE®) technology, is making significant strides in the clinical development of novel therapies targeting solid and liquid tumors. With over 500 patients treated, the company has demonstrated clinical efficacy across various indications, leveraging its proprietary IP targeting CD16A on NK cells and macrophages. Affimed's pipeline includes promising candidates like AFM24, AFM13, and AFM28, each showing potential in addressing significant unmet needs in cancer treatment, particularly in non-small cell lung cancer (NSCLC), Hodgkin lymphoma (HL), and acute myeloid leukemia (AML).